Home/Pipeline/Connexus BCI

Connexus BCI

Communication restoration in severe paralysis (ALS, stroke, spinal cord injury)

Early Feasibility StudyActive

Key Facts

Indication
Communication restoration in severe paralysis (ALS, stroke, spinal cord injury)
Phase
Early Feasibility Study
Status
Active
Company

About Paradromics

Paradromics is a clinical-stage medical device company pioneering a high-bandwidth, scalable brain-computer interface platform. The company's core technology focuses on high-channel-count, single-neuron recording combined with advanced AI decoding algorithms, with an initial application targeting speech restoration. Having received FDA Breakthrough Device Designation and IDE approval, Paradromics is advancing its lead product, Connexus BCI, into clinical studies, positioning it as a key player in the competitive neuroprosthetics landscape. The company blends deep technical expertise from academia and DARPA with seasoned medical device leadership to navigate the complex path to commercialization.

View full company profile